YBX1 and breast cancer: In response to everolimus (mTORC1 inhibitor) or TAS0612 (multikinase inhibitor of AKT, p70S6K, and p90RSK), YBX1 phosphorylation at S102 was downregulated together with the inhibited cell growth and abrogated antiestrogen resistance in breast cancer cells [32].